Grid picks Catalent to make mAb for solid tumours

By Flora Southey

- Last updated on GMT


Related tags Cancer Immune system Lung cancer

Grid Therapeutics has selected Catalent Pharma Solutions to develop and manufacture its antibody candidate to treat solid tumours.

Under the agreement, Catalent will use its GPEx technology to develop the cell line for Grid, and perform development activities through to drug manufacturing.

Catalent’s Rob Gustines told us Grid will be responsible for the commercialisation of the mAb.

“Catalent’s role is to support the development of the antibody for Grid Therapeutics, who will determine the future of the programme’s commercialisation,” ​Gustines told us.

The project – sponsored by Grid – will be undertaken at Catalent’s Madison, Wisconsin-based manufacturing site.

IgG mAb

Grid identifies its tumour immunoglobulin G (IgG) antibodies from patients with early stage cancer.

“The antibody was discovered in exceptional outcome early stage lung cancer patients who did not progress to develop metastasis,” ​said Grid.

Grid’s lead candidate is the first human derived targeted immunotherapy for cancer.

Last month, Catalent announced​ it would buy Cook Pharmica to expand its biologics, cell culture manufacturing and packaging capabilities.

Related news

Show more

Related products

show more

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 01-Jan-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 06-Dec-2022 | Product Brochure

Your biologics possess a high level of complexities and technical challenges. That’s why development is key to ensuring the successful delivery of your...

Related suppliers

Follow us


View more